Fact.MR forecasts global breast cancer diagnostics sales to exceed US$7.9 billion at a CAGR of 7% for the forecast period 2022-2032. The demand for cost-effective, technologically advanced, efficient and accurate diagnostic solutions is expected to be a major trend in the industry over the course of the decade.
Historically, the demand for breast cancer diagnostics has thrived at a CAGR of 6% from 2017 to 2021. Healthcare infrastructure around the world took a hit as the coronavirus became a global pandemic in the first quarter of 2020. Every nation had to rethink its health strategies, leading to sweeping reforms around the world. With the increasing prevalence of cancer cases worldwide, the general population has increased demand for effective measures to treat and diagnose breast cancer, and governments are focused on making these solutions widely and cost-effectively available.
To stay one step ahead of your competitors, request a sample – https://www.factmr.com/connectus/sample?flag=S&rep_id=55
Breast cancer diagnostics providers are focused on developing new tools and devices that facilitate early detection of breast cancer, which is critical to effectively combating the disease. Investment in research is also expected to increase significantly over the next decade as the focus shifts to treating and fighting breast cancer.
Important insights from the market study
- By test type, the CEA test is expected to hold more than 45% market share for breast cancer diagnostics
- In terms of end users, hospital laboratories expect a market share of more than 50% in the market for breast cancer diagnostics.
- The breast cancer diagnostics industry is expected to have nearly 45% market share across North America.
- The breast cancer diagnostics industry is expected to have a market share of almost 40% in Asia-Pacific.
- The global breast cancer diagnostics market is projected to reach $4 billion by the end of 2022
Key Segments Covered in Breast Cancer Diagnostics…
